Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study

The objective of this study was to evaluate the efficacy and safety profile of weekly docetaxel, estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer. Forty-eight patients received 35 mg m(−2) of weekly docetaxel for 3 out of every 4 weeks, 280 mg of estramustine t...

Descripción completa

Detalles Bibliográficos
Autores principales: Carles, J, Font, A, Mellado, B, Domenech, M, Gallardo, E, González-Larriba, J L, Catalan, G, Alfaro, J, Gonzalez del Alba, A, Nogué, M, Lianes, P, Tello, J M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360463/
https://www.ncbi.nlm.nih.gov/pubmed/17955053
http://dx.doi.org/10.1038/sj.bjc.6604030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360463/
https://www.ncbi.nlm.nih.gov/pubmed/17955053
http://dx.doi.org/10.1038/sj.bjc.6604030

Ejemplares similares